Manel Juan on Muck Rack

Manel Juan

Spain
As seen in: Nature, Color Research & Application, ScienceDirect, SPORT, El Periódico, Cell Reports Medicine, La Nueva España, Levante-El Mercantil Valenciano, Diario Información, La Opinión de Zamora, Diario de Mallorca and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Manel

Contact Manel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancer

|
By Natalia Díaz-Valdivia, Paula Duch, Rafael Ikemori, Amelia Parker, Marselina Arshakyan, Alejandro Llorente, Alejandro García Bernardo, José Rodríguez-Rojas, Josep Lluís Carrasco, Danielle Park, Erik Sahai, Cristina Fillat, Manel Juan, Ernest Nadal, Noemí Reguart, Derek C. Radisky, Oriol Casanovas, Jordi Alcaraz
| Nature
Abstract Non-small cell lung cancer (NSCLC) exhibits disparate responses to anti-angiogenic therapies between its two major histologic subtypes, lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), suggesting a histotype-dependent angiogenesis regulation. Tumor-associated fibroblasts (TAFs) exhibit an activated/myofibroblast-like phenotype in NSCLC, and are emerging as major regulators of tumor progression; yet, their role in controlling angiogenesis in NSCLC remains undefined.
Open in Who Shared Issue with article?

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) | Nature Communications

|
By Tomás Pascual, Maria Espie Vidal, María Vidal , Juan M. Cejalvo, Estela Vega, Esther Sanfeliu, Guillermo Villacampa, Sergi Ganau, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Elia Seguí, Manel Juan, Patricia Galván, Samyukta Chillara, Patricia Villagrasa, Adam D. Pfefferle, Mafalda Oliveira, Charles M. Perou, Aleix Prat, Fara Brasó-Maristanty, Xavier Gonzàlez-Farré, Constandina E. O’Connell, Juan M. Ferrero-Cafiero
| Nature
Abstract This single-arm, phase II, preoperative window-of-opportunity trial (ClinicalTrials.gov Identifier: NCT03802604) investigated the efficacy and safety of talimogene laherparepvec (T-VEC), an oncolytic virus, with atezolizumab, an anti–PD-L1 antibody, in patients with breast cancer and radiologically and pathologically confirmed residual disease prior to surgery.
Open in Who Shared Issue with article?

Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition | Bone Marrow Transplantation

|
By Jesus Fernandez-Sojo, Virginia Gómez , Manel Juan, Thomas Larsen, Daniel H. Lysak, Mirko Müller, Florent Malard, Annalisa Ruggeri, Ganesh Ramesh, Petr Lesný, Sofieke de Wilde
| Nature
TO THE EDITOR: Viral vectors, including γ-retroviruses (γ-RVs), lentiviruses (LVs), adeno-associated viruses (AAVs), and adenoviruses (AVs), are the most widely used gene delivery platforms in advanced therapy medicinal product (ATMP) development [1,2,3,4] and for approved therapies [5,6,7]. However, the extent of GMP-capable manufacturing capacity in European academic centers remains unclear.
Open in Who Shared Issue with article?
See all 322 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Manel

Contact Manel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified